FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3165260160> ?p ?o ?g. }

• W3165260160 endingPage "1332" @default.
• W3165260160 startingPage "1319" @default.
• W3165260160 abstract "Netakimab (NTK), an original humanized anti-interleukin-17 monoclonal antibody, showed therapeutic efficacy in moderate-to-severe plaque psoriasis in a phase 2 clinical study. Herein we report the results of 54 weeks of a phase 3 PLANETA trial aimed to evaluate the efficacy and safety of two NTK regimens vs. placebo. Two hundred thirteen patients with moderate-to-severe plaque psoriasis were randomly assigned to receive NTK 120 mg once every 2 weeks (NTK Q2W), NTK 120 mg once every 4 weeks (NTK Q4W) or placebo. During the first 3 weeks, patients received subcutaneous injections of NTK or placebo (according to the allocation) once a week. Patients in the NTK Q2W group then received NTK at weeks 4, 6, 8 and 10. Subjects in the NTK Q4W group received NTK at weeks 6 and 10 and placebo at weeks 4 and 8. Patients in the placebo group received placebo injections at weeks 4, 6, 8 and 10. Treatment was unblinded at week 12. During the open-label phase, patients in both NTK groups continued to receive NTK Q4W. The primary efficacy endpoint was the proportion of patients in each group who achieved a ≥ 75% reduction from baseline in psoriasis area and severity index (PASI 75) at week 12. A total of 77.7%, 83.3% and 0% of patients had a PASI 75 response at week 12 in the NTK Q2W, NTK Q4W and placebo groups, respectively (P < 0.0001, Fisher’s exact test, ITT). The effect was maintained throughout the 1-year treatment. NTK showed a good safety profile and low immunogenicity. Treatment with NTK results in high rates of sustained clinical response in patients with moderate-to-severe plaque psoriasis. The study is ongoing; thus, long-term use efficacy and safety data are forthcoming. The trial is registered at the US National Institutes of Health (ClinicalTrials.gov; NCT03390101)." @default.
• W3165260160 created "2021-06-07" @default.
• W3165260160 creator A5025897190 @default.
• W3165260160 creator A5026365582 @default.
• W3165260160 creator A5031853679 @default.
• W3165260160 creator A5044974383 @default.
• W3165260160 creator A5056024874 @default.
• W3165260160 creator A5057948194 @default.
• W3165260160 creator A5059865179 @default.
• W3165260160 creator A5066305320 @default.
• W3165260160 creator A5073745774 @default.
• W3165260160 creator A5089142448 @default.
• W3165260160 creator A5090816037 @default.
• W3165260160 date "2021-05-31" @default.
• W3165260160 modified "2023-10-16" @default.
• W3165260160 title "Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial" @default.
• W3165260160 cites W1986328617 @default.
• W3165260160 cites W2160247072 @default.
• W3165260160 cites W2418506270 @default.
• W3165260160 cites W2977368346 @default.
• W3165260160 cites W2981300797 @default.
• W3165260160 cites W4239041866 @default.
• W3165260160 doi "https://doi.org/10.1007/s13555-021-00554-4" @default.
• W3165260160 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8322379" @default.
• W3165260160 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34060012" @default.
• W3165260160 hasPublicationYear "2021" @default.
• W3165260160 type Work @default.
• W3165260160 sameAs 3165260160 @default.
• W3165260160 citedByCount "20" @default.
• W3165260160 countsByYear W31652601602021 @default.
• W3165260160 countsByYear W31652601602022 @default.
• W3165260160 countsByYear W31652601602023 @default.
• W3165260160 crossrefType "journal-article" @default.
• W3165260160 hasAuthorship W3165260160A5025897190 @default.
• W3165260160 hasAuthorship W3165260160A5026365582 @default.
• W3165260160 hasAuthorship W3165260160A5031853679 @default.
• W3165260160 hasAuthorship W3165260160A5044974383 @default.
• W3165260160 hasAuthorship W3165260160A5056024874 @default.
• W3165260160 hasAuthorship W3165260160A5057948194 @default.
• W3165260160 hasAuthorship W3165260160A5059865179 @default.
• W3165260160 hasAuthorship W3165260160A5066305320 @default.
• W3165260160 hasAuthorship W3165260160A5073745774 @default.
• W3165260160 hasAuthorship W3165260160A5089142448 @default.
• W3165260160 hasAuthorship W3165260160A5090816037 @default.
• W3165260160 hasBestOaLocation W31652601601 @default.
• W3165260160 hasConcept C126322002 @default.
• W3165260160 hasConcept C142724271 @default.
• W3165260160 hasConcept C16005928 @default.
• W3165260160 hasConcept C185592680 @default.
• W3165260160 hasConcept C204243189 @default.
• W3165260160 hasConcept C204787440 @default.
• W3165260160 hasConcept C27081682 @default.
• W3165260160 hasConcept C2777011040 @default.
• W3165260160 hasConcept C2780564577 @default.
• W3165260160 hasConcept C535046627 @default.
• W3165260160 hasConcept C71924100 @default.
• W3165260160 hasConcept C90924648 @default.
• W3165260160 hasConceptScore W3165260160C126322002 @default.
• W3165260160 hasConceptScore W3165260160C142724271 @default.
• W3165260160 hasConceptScore W3165260160C16005928 @default.
• W3165260160 hasConceptScore W3165260160C185592680 @default.
• W3165260160 hasConceptScore W3165260160C204243189 @default.
• W3165260160 hasConceptScore W3165260160C204787440 @default.
• W3165260160 hasConceptScore W3165260160C27081682 @default.
• W3165260160 hasConceptScore W3165260160C2777011040 @default.
• W3165260160 hasConceptScore W3165260160C2780564577 @default.
• W3165260160 hasConceptScore W3165260160C535046627 @default.
• W3165260160 hasConceptScore W3165260160C71924100 @default.
• W3165260160 hasConceptScore W3165260160C90924648 @default.
• W3165260160 hasIssue "4" @default.
• W3165260160 hasLocation W31652601601 @default.
• W3165260160 hasLocation W31652601602 @default.
• W3165260160 hasLocation W31652601603 @default.
• W3165260160 hasLocation W31652601604 @default.
• W3165260160 hasOpenAccess W3165260160 @default.
• W3165260160 hasPrimaryLocation W31652601601 @default.
• W3165260160 hasRelatedWork W2032633556 @default.
• W3165260160 hasRelatedWork W2060142842 @default.
• W3165260160 hasRelatedWork W209027 @default.
• W3165260160 hasRelatedWork W2165746902 @default.
• W3165260160 hasRelatedWork W2331028526 @default.
• W3165260160 hasRelatedWork W2588369178 @default.
• W3165260160 hasRelatedWork W2781166685 @default.
• W3165260160 hasRelatedWork W3022724713 @default.
• W3165260160 hasRelatedWork W3176363967 @default.
• W3165260160 hasRelatedWork W2343185506 @default.
• W3165260160 hasVolume "11" @default.
• W3165260160 isParatext "false" @default.
• W3165260160 isRetracted "false" @default.
• W3165260160 magId "3165260160" @default.
• W3165260160 workType "article" @default.